• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Late-stage trial fails for Aradigm’s inhaled antibiotic

December 1, 2016 By Sarah Faulkner

Late-stage trial fails for Aradigm's inhaled antibioticAradigm Corp. (NSDQ:ARDM) said today that its inhaled antibiotic failed in a late-stage clinical trial, sending the Hayward, Calif.-based company’s stock down -54% in premarket trading.

Pulmaquin is a once-daily formulation containing ciprofloxacin, a widely prescribed broad-spectrum antibiotic. The inhaled drug was being tested to treat patients with non-cystic fibrosis bronchiectasis (non-CF BE) who have chronic lung infections from the bacteria P. aeruginosa. The infection leads to the enlargement of the lungs’ airways.

The company was evaluating Pulmaquin in 2 late-stage trials: Orbit-3 and Orbit-4. The goal of both trials was to see an increase in the time taken until the 1st instance of pulmonary exacerbation. In Orbit-3, Pulmaquin outperformed the placebo but the difference wasn’t statistically significant. In Orbit-4, however, Pulmaquin did have a statistically significant benefit over the placebo, as patients given Pulmaquin recorded a median time of 230 days until the 1st pulmonary exacerbation, whereas patients given a placebo took 163 days.

While there were 8 deaths in Orbit-3 and 6 in Orbit-4, Aradigm said none of the deaths were related to the inhaled antibiotic.

Pulmaquin, which was awarded orphan drug and fast track status by the FDA, and other inhaled ciprofloxacin formulations are also being evaluated to treat cystic fibrosis and non-tuberculous mycobacteria. The antibiotic is also being looked at as a possible candidate to prevent and treat bioterrorism infections, including inhaled tularemia and pneumonic plague.

ARDM shares were trading at $2.27 in early afternoon activity, down -56.7%.

Filed Under: Clinical Trials, Featured, Respiratory Tagged With: Aradigm Corp.

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS